Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Europe Pre-Open: Futures FTSE +0.13%, DAX +0.33%, CAC40 +0.13%

Sep 17 ,2025

  • Synopsis

    • European equity markets are set for a positive open amidst mostly lower Asia equities Wednesday. Hong Kong leading with sharp gains in a tech-driven rally as mainland China swung positive. Japan leaning to losses and most other benchmarks weaker. US contracts softened marginally though still generally little changed following moderate overnight losses that saw S&P and Nasdaq fading slightly off Monday's record highs; Nasdaq 100 index was down after nine straight days of gains.

    • US President Trump is set to meet King Charles in Windsor Castle as part of his first full day during second state visit.

    • In central banks, ECB's Lagarde speech at 9:30CET at 10th ECB Annual Research Conf. and Cipollone speech at 13:15 at Netherlands central bank's Resilience Conf. Croatia central bank's Vujčić panellist at 11:30 CET at event organised by Croatian trade unions topic "The impact of inflation and interest rates on wage policy and the position of employees in the Republic of Croatia". Bundesbank's Nagel speech at 19:00CET at event hosted by Harvard Clubs of Germany. In Switzerland, SECO may release its latest economic forecast (through the provisional calendar has the release in Oct). UK in a Change Europe hosts event The future of UK-EU relations.

    • Macro data due include Sweden Aug unemployment rate, UK Aug CPI, RPI, Eurozone and Austria Aug final CPI.

    • On a light corporate front, PostNL (PNL.NA) is hosting its CMD and guided FY28 normalised EBIT of €175M. In France,

    • VINCI (DG.FP) reported August airport passenger traffic +5.2%, y/y and Innate Pharma (IPH.FP) reported H1 net income (€21.3M) vs FactSet (€26.2M).

  • Macro

    • Trump arrives in Britain for second state visit - Guardian; Reuters

    • EU to propose faster phase-out of Russian energy, von der Leyen says - Reuters

  • Top company news

    • Earnings/updates

      • Benelux:

        • PNL.NA (PostNL) -- expects FY28 normalised EBIT of €175M -- CMD

      • France:

        • ALSEN.FP (Sensorion) -- reports H1 net income (€16.0M) vs year-ago (€13.9M)

        • DG.FP (VINCI SA) -- reports August airport passenger traffic +5.2%, y/y

        • IPH.FP (Innate Pharma) -- reports H1 net income (€21.3M) vs FactSet (€26.2M) [1 est]

        • TNG.FP (Transgene) -- reports H1 net income (€19.3M) vs year-ago (€16.5M)

    • M&A

      • MYTIL.GA (Metlen Energy & Metals) -- Engie seeking to acquire Metlen Energy & Metals' Australian renewables portfolio - Australian Financial Review

      • ENGI.FP (Fnac Darty) -- submits offer to acquire Engie Home Services -- BFMTV

      • EQNR.NO (Equinor) -- acquires Koch's direct lithium extraction business; terms not disclosed

      • MBTN.SW (Meyer Burger Technology) -- notes silent debt moratorium previously granted to its Swiss companies will be continued as regular provisional debt moratorium

      • INTEG.B.SS (Integrum) -- OsteoCentric reports Integrum tender offer will not be completed as the 90% acceptance condition was not satisfied; Integrum disagrees

      • V3V.GR (FamiCord) -- subsidiary Polski Bank Komórek Macierzystych to acquire 100% of the shares in the stem cell bank "nOvum"

      • TikTok's US operations to be controlled by investor consortium including Oracle, Silver Lake and Andreessen Horowitz - Bloomberg

    • Healthcare

      • UCB.BB (UCB) -- announces BIMZELX data in moderate-to-severe plaque psoriasis at EADV

      • LLY (Eli Lilly) -- reports detailed results from Phase 3 ATTAIN-1 trial, the investigational once-daily oral pill led to average weight loss of 27.3 lbs (12.4%) at highest dose at week 72 in the Phase 3 study

      • SAN.FP (Sanofi) -- Sanofi's brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study

      • CYTK (Cytokinetics) -- participates in late cycle meeting with FDA; continues to expect a differentiated label and risk mitigation profile for aficamten, if approved - 8-K

      • SOBI.SS (Swedish Orphan Biovitrum) -- Transcript Intelligence: Swedish Orphan Biovitrum Business Update Call

      • TNG.FP (Transgene) -- Transgene's Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Delivers Positive Randomized Phase I Data; Randomization to be Completed in Phase II Part in Q4 2025

      • FYB.GR (Formycon) -- concludes additional semi-exclusive license agreement with Horus Pharma for commercialization of FYB203/Baiama in selected European countries

      • BICO.SS (BICO Group) -- BICO Group's board elects Maria Rankka as Chair

    • Other

      • BWE.NO (BW Energy) -- appoints Brice Morlot as COO and Thomas Young as CFO

      • DEME.BB (DEME) -- signs €50M contract to reinforce the Lekdijk in the Netherlands

      • NDX1.GR (Nordex Group) -- enters Ecuadorian market with first order for 112 MW wind project

      • HEX.NO (Hexagon Composites) -- announces 6.0M new shares subsequent offering at NOK14 per share, following successful completion of 42.0M new shares private placement

      • SAP.GR (SAP) -- Transcript Intelligence: SAP at Jefferies Structural Winners Series

      • NESN.SW (Nestle) -- Chairman Paul Bulcke to step down

      • VOW.GR (Volkswagen) -- subsidiary Audi faces a tax burden in the US this year that could total more than one billion euros -- Handelsblatt, citing company sources

      • ML.FP (Cie Generale des Etablissements Michelin SA) -- Michelin publishes global tire market data for Aug

      • LHA.GR (Deutsche Lufthansa) -- Lufthansa proposes to elect Johannes Teyssen as Chairman of the Supervisory board and succeed Karl-Ludwig Kley effective 12-May-26 (16-Sep, ~17:00 CET)

      • SAB.SM (Banco de Sabadell) -- Transcript Intelligence: Banco de Sabadell at Bank of America Financials CEO Conference

      • Intraday themes include BWX uranium pilot contract and EPA to released plan on exempted biofuel volumes (16-Sep)

      • Regional Gaming Revenues - New Jersey August 2025

  • Key rating changes

    • Upgrades

      • GRE.SM (Grenergy Renovables) -- buy from hold at Bestinver Securities

      • CNA.LN (Centrica) -- overweight from equal-weight at Morgan Stanley

      • DSV.DC (DSV A/S) -- to buy from hold at ABG Sundal Collier

      • ITX.SM (Inditex) -- to buy from neutral at UBS

    • Downgrades

      • Morgan Stanley downgrades SOLB.BB, WCH.GR

      • NHY.NO (Norsk Hydro) -- to hold from buy at ABG Sundal Collier

    • Initiations

      • BNP Paribas Exane initiates COTN.SW; downgrades TPE.GR

      • YUBICO.SS (Yubico) -- buy at ABG Sundal Collier

      • TRUE.B.SS (Truecaller) -- buy at ABG Sundal Collier

      • IDR.SM (Indra Sistemas) -- buy at Berenberg

    • Other Actions

      • EKOP.BB (Ekopak) -- resumed reduce at Kepler Cheuvreux

  • Data

    • Nikkei (0.26%) to 44785.25

    • Hang Seng +1.70% to 26887.51

    • Shanghai Composite +0.27% to 3872.36

    • S&P futures (2.3) vs prior close of 6667.5

    • €-$ (0.0010) or (0.09%) to 1.1858

    • $-¥ +0.06 or +0.04% to 146.53

    • €-¥ (0.08) or (0.05%) to 173.74

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE